Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Operating Expenses (2021 - 2025)

Historic Operating Expenses for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to $55.2 million.

  • Prime Medicine's Operating Expenses rose 139.05% to $55.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.9 million, marking a year-over-year decrease of 755.08%. This contributed to the annual value of $205.4 million for FY2024, which is 32.13% up from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Operating Expenses is $55.2 million, which was up 139.05% from $54.5 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Operating Expenses ranged from a high of $68.0 million in Q4 2023 and a low of $10.4 million during Q3 2021
  • Moreover, its 5-year median value for Operating Expenses was $48.9 million (2024), whereas its average is $44.8 million.
  • Data for Prime Medicine's Operating Expenses shows a peak YoY increase of 20358.68% (in 2022) and a maximum YoY decrease of 3560.49% (in 2022) over the last 5 years.
  • Prime Medicine's Operating Expenses (Quarter) stood at $60.1 million in 2021, then plummeted by 35.6% to $38.7 million in 2022, then soared by 75.89% to $68.0 million in 2023, then tumbled by 31.8% to $46.4 million in 2024, then rose by 18.95% to $55.2 million in 2025.
  • Its Operating Expenses stands at $55.2 million for Q3 2025, versus $54.5 million for Q2 2025 and $53.8 million for Q1 2025.